All In Biotech

Drug Trial Radar · NCT04225598

Emergency Department-Initiated Buprenorphine Validation Network Trial

Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,000

Actual

Start

Jul 8, 2020

Primary completion

Dec 6, 2024

Study completion Dec 6, 2024

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Drug Abuse Treatment Clinical Trials Network; The Emmes Company, LLC; Harvard Medical School (HMS and HSDM); University of Pennsylvania; NYU Langone Health; Icahn School of Medicine at Mount Sinai; Alameda Health System; Weill Medical College of Cornell University; National Institute on Drug Abuse (NIDA)
First posted
Jan 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S. using implementation facilitation strategies to provide ED-initiated buprenorphine (BUP) for patients presenting with opioid use disorder (OUD) who are not receiving medications for opioid use disorder (MOUD). Once implementation is adequately achieved, the sites will (2) conduct a randomized controlled trial (RCT) to compare the effectiveness of sublingual buprenorphine (SL-BUP) versus extended-release buprenorphine (XR-BUP) on ED patients' engagement in formal addiction treatment 7-days after their ED visit. In addition, in an ancillary component of the study, the investigators will (3) assess the use of XR-BUP in ED patients with Clinical Opioid Withdrawal Scale (COWS) scores \< 8 in a case series to potentially expand the eligibility of patients in the larger RCT to those presenting with little to no opioid withdrawal symptoms. Finally, the investigators will (4) develop and validate ED electronic health record (EHR) opioid-related phenotypes, both of which will inform the main RCT.

Conditions

  • Opioid-use Disorder

Interventions

  • CAM2038Drug

    Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.

  • Buprenorphine Sublingual ProductDrug

    COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS \>≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder). COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RCT Component: Patient engagement (yes/no) in formal addiction treatment at 7 days post randomizationTime frame: 7 days post randomization

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Highland Hospital

    Oakland, California

  • San Leandro Hospital

    San Leandro, California

  • Yale New Haven Health (Yale New Haven Hospital)

    New Haven, Connecticut

  • Jackson Memorial Hospital

    Miami, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Grady Memorial Hospital

    Atlanta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • University of Chicago Medicine

    Chicago, Illinois

  • Maine Medical Center

    Portland, Maine

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Detroit Receiving Hospital

    Detroit, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Hennepin County Medical Center

    Minneapolis, Minnesota

  • Barnes Jewish Hospital

    St Louis, Missouri

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Cooper University Hospital

    Camden, New Jersey

  • Presybterian Hospital, Albuquerque, NM

    Albuquerque, New Mexico

  • University of New Mexico Hospital

    Albuquerque, New Mexico

  • Bellevue Hospital

    New York, New York

  • Icahn School of Medicine

    New York, New York

  • Columbia University Irving Medical Center- NY Presbyterian

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Upstate Medical University

    Syracuse, New York

  • Duke University

    Durham, North Carolina

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina

  • Pennsylvania Presbyterian Medical Center/Hospital of UPENN

    Philadelphia, Pennsylvania

  • Temple University Hospital - Episcopal Campus

    Philadelphia, Pennsylvania

  • UPMC Mercy Hospital

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital/The Miriam Hospital

    Providence, Rhode Island

  • Medical University of South Carolina

    Charleston, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Parkland Memorial Hospital

    Dallas, Texas

  • University of Utah Hospital

    Salt Lake City, Utah

  • University of Washington Medical Center- Harborview/Montlake

    Seattle, Washington

  • West Virginia University - Berkeley Medical Center

    Martinsburg, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.